AstraZeneca (LON:AZN) Stock Keeps Buy Rating at Berenberg Bank

AstraZeneca (LON:AZN)‘s stock had its “buy” rating restated by Berenberg Bank in a note issued to investors on Wednesday, Digital Look reports. They presently have a £175 price target on the biopharmaceutical company’s stock. Berenberg Bank’s target price would indicate a potential upside of 45.86% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the company. Jefferies Financial Group reissued a “buy” rating and set a £175 price target on shares of AstraZeneca in a report on Wednesday, September 9th. Citigroup upped their price objective on AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a research note on Tuesday, July 28th. Royal Bank Of Canada reiterated an “outperform” rating and set a £145 target price on shares of AstraZeneca in a research report on Tuesday, September 8th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a £117 target price on shares of AstraZeneca in a research report on Tuesday, September 29th. Six research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of £153.57.

AstraZeneca Price Performance

AstraZeneca stock traded up GBX 106 during mid-day trading on Wednesday, hitting £119.98. The stock had a trading volume of 4,449,107 shares, compared to its average volume of 29,147,215. AstraZeneca has a one year low of £114.04 and a one year high of £157.32. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 64.10. The firm has a market capitalization of £186.08 billion, a P/E ratio of 17.96, a P/E/G ratio of 0.86 and a beta of 0.20. The firm’s 50 day moving average is £120.45 and its 200 day moving average is £131.98.

Insider Buying and Selling

In related news, insider Michel Demare purchased 2,500 shares of the firm’s stock in a transaction on Monday, September 14th. The shares were acquired at an average price of £121.21 per share, for a total transaction of £303,025. 0.15% of the stock is currently owned by insiders.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.